<DOC>
	<DOCNO>NCT00062751</DOCNO>
	<brief_summary>To evaluate preliminary activity pharmacokinetics 2 separate dos schedule orally administer Temsirolimus ( CCI-779 ) give combination daily letrozole , compare letrozole alone , treatment locally advance metastatic breast cancer postmenopausal woman . All patient must appropriate receive endocrine therapy treatment advance disease .</brief_summary>
	<brief_title>Study Evaluating Temsirolimus ( CCI-779 ) In Breast Neoplasms</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Postmenopausal woman histologically confirm , measurable locally advanced disease metastatic breast . Must appropriate receive endocrine therapy treatment advanced disease ( chemotherapy ; prior adjuvant therapy antiestrogens aromatase inhibitor ; prior adjuvant firstline metastatic therapy tamoxifen trastuzumab , permit ) . Women may either present de novo advanced metastatic cancer , tumor progression receive adjuvant tamoxifen time complete adjuvant tamoxifen , tumor progression receive firstline metastatic therapy tamoxifen . Patients known central nervous system ( CNS ) metastases . Prior therapy Temsirolimus ( CCI779 ) aromatase inhibitor . Tamoxifen , hormonal therapy , metastatic adjuvant set within 1 week prior day 1 treatment study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>breast</keyword>
	<keyword>neoplasm</keyword>
</DOC>